Loading...

Evolus, Inc.

EOLS•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$5.30
$-0.01(-0.19%)
U.S. Market opens in NaNh NaNm

Evolus, Inc. (EOLS) Stock Overview

Explore Evolus, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap344.8M
P/E Ratio-6.53
EPS (TTM)$-0.80
ROE2.68%
Fundamental Analysis

AI Price Forecasts

1 Month$4.78
3 Months$0.00
1 Year Target$0.00

EOLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Evolus, Inc. (EOLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 65.94, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.53 and a market capitalization of 344.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.19%
5-Day Change
13.98%
1-Month Change
19.64%
3-Month Change
7.72%
6-Month Change
-21.94%
Year-to-Date (YTD) Change
-20.30%
1-Year Change
-54.11%
3-Year Change
-39.15%
5-Year Change
-43.29%
All-Time (Max) Change
-53.91%

Contact Information

https://www.evolus.com
949 284 4555
520 Newport Center Drive, Newport Beach, CA, 92660

Company Facts

372 Employees
IPO DateFeb 8, 2018
CountryUS
Actively Trading

Frequently Asked Questions